Telomere Targeting Immunotherapies for Cancer. Link to: About Us. About Us

Dec 19, 2024 · MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully …

MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve...

Maia Biotechnology is a public, Texas based, immune-oncology company. [1] It is led by CEO/Chairman Vlad Vitoc, MD, MBA and Chief Scientific Officer Sergei M. Gryaznov, PhD. In August 2022, the company's initial funding round closed, raising $10M. [2] .

MAIA Biotechnology, Inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.

3 days ago · About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer ...

3 days ago · CHICAGO, February 04, 2025--MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer. CHICAGO, February 04, 2025--MAIA Biotechnology ...

Our pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers (select a program to learn more). 1 Phase 2 Basket / Umbrella design – for accelerated approval in U.S.

Jan 17, 2024 · CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, announced new interim data for its ongoing THIO-101 Phase 2 trial in non-small cell lung cancer (NSCLC) and outlined key clinical milestones for 2024.

3 days ago · About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer ...